Home

Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes...

Tailwinds' Take: Fortress' value add is in finding underdeveloped drugs that have excellent scientific research and bringing them through the FDA process and to...

ChromaDex Achieves New Regulatory Milestones in the European Union & Australia

Tailwinds' Take: we remain believers in Tru Niagen and think it has a bright future. When we think the company is financed through to...

MTBC, Inc. Provides 2020 Guidance, Growth of 50% or Greater Expected

Tailwinds' Take: This guidance puts MTBC at around 6 times 2020 EBITDA. Growth by acquisition is working well for these guys, who are excellent...

HyreCar Provides Update on Fourth Quarter 2019 Revenue

Tailwinds' Take: as we anticipated, revenue re-accelerated in Q4. 2020 is looking to be a solid year for HYRE as their OEM and dealer...

RESONANT POWER HANDLING INNOVATION LOWERS RF FILTER COSTS FOR HIGH-POWER 4G DEVICES

GOLETA, CA / ACCESSWIRE / January 13, 2020 / Resonant Inc.(NASDAQ:RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and...

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell...

Tailwinds' Take: the many shots on goal under the FBIO umbrella is one of the most compelling aspects of the company. This is great...

Journey Medical Corporation Recaps 2019 Growth

Tailwinds' Take: Journey is growing rapidly as they execute on the overall strategy of FBIO; licensing low-risk products and bringing them to market. This...

US AND CHINA – THE TECH WARS AHEAD

Technological progress benefits all of humanity in terms of lifespans and health, the ability to travel and communicate—the whole cornucopia of goods and services...

MTBC Announces Acquisition of CareCloud, Closes its Largest Transaction to Date

SOMERSET, N.J., Jan. 08, 2020 (GLOBE NEWSWIRE) -- MTBC, Inc. (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of cloud-based healthcare IT and revenue cycle management solutions,...

Provention Bio Appoints Jason Hoitt as Chief Commercial Officer

Tailwinds' Take: Provention continues to build a team around the massive opportunity of tepluzimab. Hoitt has an impressive resume. We view his addition very...

Hancock Jaffe Reports Positive Results For 6 Month CoreoGraft Animal Feasibility Study

Tailwinds' Take: this is outstanding news. Once again the science at HJLI is showing a dramatic divergence from the crazy-low valuation. After their funding...

INmune’s Efforts in Alzheimer’s…Low Risk to Phase 1b Success???

In December of 2019, INmune Bio (INMB) commenced dosing of humans in a Phase 1b trial of XPro1595 (XPro), a drug targeting Alzheimer’s Disease....

WiSA Enables the Future of Speakerless TVs with Demo of Sharp’s WiSA Ready 8K...

Tailwinds' Take: this is potentially very big news. Sharp is now owned by Foxconn, the world's largest electronics manufacturing firm. Having them endorse speakerless...

WiSA Fuels the Growing Wireless Audio Category; CES Showcase Highlights the Future of Home...

Tailwinds' Take: we expect the WiSA standard to make a big splash at CES2020. This is the future of home entertainment systems. LAS VEGAS--(BUSINESS WIRE)-- Consumer...

RESONANT INC. EXPANDS RELATIONSHIP WITH EXISTING CUSTOMER BY SIGNING NEW LICENSE AGREEMENTS

Tailwinds Take: the rate of adoption of Resonant's designs continues to be unimpressive. The key to this story remains 5G and that rollout is...

Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference

SAN JOSE, Calif., Jan. 6, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the...

What to Expect When Everyone’s Expecting (An Up Market)

What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us...

Nmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to...

Tailwinds' Take: more solid data that should translate very well into humans. Remember, INmune has an ongoing Phase 1b trial in Alzheimer's Disease right...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

Bioasis Completes Bridge Financing Transaction

Tailwinds' Take: needed financing to keep things going until they can land a strategic investor. The clock is ticking on my ability to hold...

Become a Tailwinds Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $250 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.